Biotechnology
CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells
KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...
2019-05-30 20:00
1992
CytoDyn and Samsung BioLogics Formalize Manufacturing Partnership
INCHEON, South Korea, May 30, 2019 /PRNewswire/ -- CytoDyn Inc., a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at the Samsung BioLogics Songdo headquarters for an official ...
2019-05-30 19:00
2536
Thermo Fisher Scientific and Scinogy Partner to Accelerate Cell and Gene Therapy Commercialization
New collaboration will enable scalable, cost-effective manufacturing processes CARLSBAD, California, May 30, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Scinogy, specialists in closed, automated manufacturing systems for...
2019-05-30 04:01
3220
Singlera Genomics ColonES test selected as finalist for AACC Disruptive Technology Award
SAN DIEGO, May 29, 2019 /PRNewswire/ -- Singlera Genomics, which focuses on non-invasive early cancer detection through circulating tumor DNA methylation haplotyping analysis, was selected as one of three finalists for the second annual AACC Disruptive Technology Award. AACC Disruptive Technolo...
2019-05-29 21:00
1247
Samsung BioLogics to Showcase End-to-End CDMO Capabilities at BIO International 2019
INCHEON, South Korea, May 28, 2019 /PRNewswire/ -- For the ninth consecutive
year since the company's foundation in 2011, Samsung BioLogics will be
showcasing its full end-to-end CDMO capabilities at the BIO International 2019
convention inPhiladelphia, PA, June 3rd to 6th.
2019-05-29 12:27
1873
Alphamab Oncology Announces Completion of US$60 Million Series B Financing
SUZHOU, China, May 28, 2019 /PRNewswire/ -- Alphamab Oncology, a leading biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, announced today that it has completed aUS$60 million Series B financing led by Hudson Bay Capital Management LP and parti...
2019-05-28 19:02
2638
Nanjing YiGenCloud Institute aims to speed up the process of China's precision medicine with "intelligence"
NANJING, China, May 27, 2019 /PRNewswire/ -- Xinjun He, Ph.D., the executive director of Nanjing YiGenCloud Institute, a leading medical big data AI company inChina, described the blueprint of their China's precision medicine at the Nature conference: Genome Variation in Precision Medicine 2019he...
2019-05-27 20:25
2296
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium
First scientific presentation of OV-935 (TAK-935) safety and tolerability data in developmental and epileptic encephalopathies from the Phase1b/2a clinical trial Study met primary safety and tolerability endpoints and showed initial evidence of potential efficacy in seizure reduction Data encou...
2019-05-24 05:04
7442
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
TAIPEI, , May 23, 2019 /PRNewswire/ -- APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson'...
2019-05-23 20:00
2942
MGI introduces total solution for single cell RNA sequencing using MGISEQ-2000 sequencing platform compatible with 10x Genomics
TOKYO, May 23, 2019 /PRNewswire/ -- MGI
2019-05-23 19:02
2922
Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress
- Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection - 8 Oral & Poster Presentations VANCOUVER, British Columbia, May 22, 2019 /PRNewswire/ -- Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris' pro...
2019-05-22 20:30
1791
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea and DALLAS, May 20, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug c...
2019-05-20 08:38
1816
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
SYDNEY, May 15, 2019 /PRNewswire/ -- NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it will initiate the Phase I clinical trial of its Stelara® (ustekinumab) biosimilar in t...
2019-05-15 20:13
1900
Hong Kong Science Park Leads Start-Up Delegation to North America's Fastest Growing Technology Conference in Toronto
HONG KONG, May 15, 2019 /PRNewswire/ -- Hong Kong Science and Technology Parks Corporation ("HKSTP") today announced that it is leading a delegation of 14 start-ups to Collision, one ofNorth America's leading technology conference, to be held inToronto, Canada from May 20 - 23, 2019. Leveraging o...
2019-05-15 16:02
2169
China Biologic Reports Financial Results for the First Quarter of 2019
--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"...
2019-05-11 04:30
9551
EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy
NEW YORK and SYDNEY, May 10, 2019 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the ...
2019-05-10 05:05
1146
GeneQuantum Healthcare completed nearly RMB 100 million in Pre-B financing
SUZHOU, China, May 7, 2019 /PRNewswire/ -- GeneQuantum Healthcare announced that it has closed nearlyRMB 100 million Pre-B round of financing. This financing was led by Huagai Capital, joined by Hofon Capital and Changjinboya. GeneQuantum Healthcare's A-round investor Oriza Seed and TF Capital co...
2019-05-08 08:00
1448
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 311 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 283 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 258 media titles]
2024-05-02 01:21
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
8059
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
6443
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
5436
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
5082
